Gaining Ground: UroGen Pharma Ltd (URGN) Closes Lower at 14.24, Down -2.73

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

The price of UroGen Pharma Ltd (NASDAQ: URGN) closed at $14.24 in the last session, down -2.73% from day before closing price of $14.64. In other words, the price has decreased by -$2.73 from its previous closing price. On the day, 0.63 million shares were traded. URGN stock price reached its highest trading level at $14.64 during the session, while it also had its lowest trading level at $13.91.

Ratios:

We take a closer look at URGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 5.65.

On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $23.Scotiabank initiated its Sector Outperform rating on April 16, 2025, with a $23 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 09 ’25 when Schoenberg Mark sold 5,162 shares for $7.37 per share. The transaction valued at 38,044 led to the insider holds 153,378 shares of the business.

Schoenberg Mark bought 5,162 shares of URGN for $38,044 on Jun 09 ’25. On Jan 31 ’25, another insider, Schoenberg Mark, who serves as the Chief Medical Officer of the company, sold 4,551 shares for $11.14 each. As a result, the insider received 50,698 and left with 145,666 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 656570816 and an Enterprise Value of 562145088. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.15. Its current Enterprise Value per Revenue stands at 6.119 whereas that against EBITDA is -5.274.

Stock Price History:

The Beta on a monthly basis for URGN is 1.11, which has changed by -0.20535713 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $18.15, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 42.62%, while the 200-Day Moving Average is calculated to be 30.19%.

Shares Statistics:

According to the various share statistics, URGN traded on average about 3.00M shares per day over the past 3-months and 1353270 shares per day over the past 10 days. A total of 46.10M shares are outstanding, with a floating share count of 39.62M. Insiders hold about 14.08% of the company’s shares, while institutions hold 96.76% stake in the company. Shares short for URGN as of 1749772800 were 6125129 with a Short Ratio of 1.82, compared to 1747267200 on 5586633. Therefore, it implies a Short% of Shares Outstanding of 6125129 and a Short% of Float of 13.56.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.